trending Market Intelligence /marketintelligence/en/news-insights/trending/bcwDZ8QJLftzJXfkNpPAfw2 content esgSubNav
In This List

Adamis resubmits new drug application to FDA for anaphylaxis treatment

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Adamis resubmits new drug application to FDA for anaphylaxis treatment

Adamis Pharmaceuticals Corp. resubmitted a new drug application to the U.S. FDA for epinephrine prefilled syringe product candidate for the emergency treatment of anaphylaxis, an extreme and severe allergic reaction.

The resubmission seeks to address issues raised by the agency in its June complete response letter.